Oxyfedrine
Oxyfedrine, a vasodilator, is an orally active β-adrenoreceptor agonist. Oxyfedrine decreases the tonicity of coronary vessels. Oxyfedrine can be used in the research of cardiovascular disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 15687-41-9
- 分子式: C19H23NO3
- 分子量:313.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Adrenergic Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
β-adrenoceptor |
体外実験
Oxyfedrine (50 μM, 48 h) suppresses aldehyde dehydrogenase (ALDH) activity in HCT116 and HSC-4 cells[1].
Oxyfedrine (50 μM, 48 h) acts as a sensitizer for GSH-depleting agents, and induces cell death in HCT116 and HSC-4 cells when with the drug combinations[1].
Oxyfedrine (0-1 μg/mL) inhibits spontaneous myogenic activity in rat isolated portal vein[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
Oxyfedrine (10 mg/kg, i.p., HCT116 cell xenograft mice) suppresses tumor growth when combined with sulfasalazine (SSZ, 350 mg/kg, i.p.)[1].
Oxyfedrine (1 mg/kg, i.v.) decreases the arterial and venous blood high blood viscosity (HBV) in ice water stress rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cats[2]
-
Dosage:14 mg/kg
-
Administration:Oral administration (p.o.), for 3-4 weeks.
-
Result:Decreased systolic and diastolic blood pressures, increased heart rate and cardiac output.
化学情報
-
CAS 番号 15687-41-9
-
分子量 313.39
-
分子式 C19H23NO3
-
SMILES
O=C(C1=CC=CC(OC)=C1)CCN[C@@H](C)[C@H](O)C2=CC=CC=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
[1]. Otsuki Y, et al. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy. Cancer Sci. 2020 Jan;111(1):127-136. [Content Brief]
[2]. Parratt JR. The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol. Br J Pharmacol. 1974 May;51(1):5-13. [Content Brief]
[3]. Yu J, et al. [Effects of oxyfedrine on high blood viscosity and myocardial necrosis induced by epinephrine and ice water stress in rats]. Zhongguo Yao Li Xue Bao. 1993 Jul;14(4):364-6. [Content Brief]
[4]. Mackenzie JE, et al. Effects of oxyfedrine on isolated portal vein and other smooth muscles. Br J Pharmacol. 1973 Apr;47(4):827-37. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Oxyfedrine 関連分類
HY-112070 関連分類
Powered by Bioz